JP2007530601A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007530601A5 JP2007530601A5 JP2007505341A JP2007505341A JP2007530601A5 JP 2007530601 A5 JP2007530601 A5 JP 2007530601A5 JP 2007505341 A JP2007505341 A JP 2007505341A JP 2007505341 A JP2007505341 A JP 2007505341A JP 2007530601 A5 JP2007530601 A5 JP 2007530601A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- optionally substituted
- alkyl
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 52
- 125000000217 alkyl group Chemical group 0.000 claims 18
- 238000000034 method Methods 0.000 claims 18
- 125000003118 aryl group Chemical group 0.000 claims 14
- 239000003814 drug Substances 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 9
- 229940079593 drug Drugs 0.000 claims 8
- 229920006395 saturated elastomer Polymers 0.000 claims 8
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 5
- 230000004770 neurodegeneration Effects 0.000 claims 5
- 208000015122 neurodegenerative disease Diseases 0.000 claims 5
- 230000000926 neurological effect Effects 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 230000002265 prevention Effects 0.000 claims 4
- 125000003342 alkenyl group Chemical group 0.000 claims 3
- 125000000753 cycloalkyl group Chemical group 0.000 claims 3
- 201000010099 disease Diseases 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 102000012440 Acetylcholinesterase Human genes 0.000 claims 2
- 108010022752 Acetylcholinesterase Proteins 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 208000018737 Parkinson disease Diseases 0.000 claims 2
- 229940022698 acetylcholinesterase Drugs 0.000 claims 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000025688 early-onset autosomal dominant Alzheimer disease Diseases 0.000 claims 2
- 230000001076 estrogenic effect Effects 0.000 claims 2
- 208000015756 familial Alzheimer disease Diseases 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 238000006396 nitration reaction Methods 0.000 claims 2
- 239000000126 substance Substances 0.000 claims 2
- 125000001255 4-fluorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1F 0.000 claims 1
- 208000018282 ACys amyloidosis Diseases 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 208000005145 Cerebral amyloid angiopathy Diseases 0.000 claims 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims 1
- 201000010374 Down Syndrome Diseases 0.000 claims 1
- 208000007487 Familial Cerebral Amyloid Angiopathy Diseases 0.000 claims 1
- 208000032849 Hereditary cerebral hemorrhage with amyloidosis Diseases 0.000 claims 1
- 208000023105 Huntington disease Diseases 0.000 claims 1
- 208000009829 Lewy Body Disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000001089 Multiple system atrophy Diseases 0.000 claims 1
- 208000024777 Prion disease Diseases 0.000 claims 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims 1
- 208000034799 Tauopathies Diseases 0.000 claims 1
- 206010044688 Trisomy 21 Diseases 0.000 claims 1
- 206010002022 amyloidosis Diseases 0.000 claims 1
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 1
- 230000001896 anti-amyloidogenic effect Effects 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 230000006999 cognitive decline Effects 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000006193 diazotization reaction Methods 0.000 claims 1
- -1 halo compound Chemical class 0.000 claims 1
- 150000004677 hydrates Chemical class 0.000 claims 1
- 206010022437 insomnia Diseases 0.000 claims 1
- 231100000518 lethal Toxicity 0.000 claims 1
- 230000001665 lethal effect Effects 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000000626 neurodegenerative effect Effects 0.000 claims 1
- 230000000324 neuroprotective effect Effects 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 238000007363 ring formation reaction Methods 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 239000012453 solvate Substances 0.000 claims 1
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004901804 | 2004-04-02 | ||
| AU2004901802 | 2004-04-02 | ||
| AU2004901804A AU2004901804A0 (en) | 2004-04-02 | Neurologically-active compounds | |
| AU2004901802A AU2004901802A0 (en) | 2004-04-02 | Process for the preparation of intermediates | |
| AU2004907359A AU2004907359A0 (en) | 2004-12-24 | Neurologically-active compounds | |
| AU2004907359 | 2004-12-24 | ||
| PCT/AU2005/000477 WO2005095360A1 (en) | 2004-04-02 | 2005-04-01 | Neurologically-active compounds |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007530601A JP2007530601A (ja) | 2007-11-01 |
| JP2007530601A5 true JP2007530601A5 (enExample) | 2009-06-25 |
| JP4937111B2 JP4937111B2 (ja) | 2012-05-23 |
Family
ID=35063693
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007505341A Expired - Fee Related JP4937111B2 (ja) | 2004-04-02 | 2005-04-01 | 神経学的に活性な化合物 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US8084459B2 (enExample) |
| EP (1) | EP1737831B1 (enExample) |
| JP (1) | JP4937111B2 (enExample) |
| BR (1) | BRPI0508183B8 (enExample) |
| CA (1) | CA2563038C (enExample) |
| DK (1) | DK1737831T3 (enExample) |
| ES (1) | ES2425476T3 (enExample) |
| IL (1) | IL178330A (enExample) |
| MX (1) | MXPA06011236A (enExample) |
| NZ (1) | NZ551004A (enExample) |
| WO (1) | WO2005095360A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1558585B1 (en) * | 2002-10-04 | 2013-09-25 | Prana Biotechnology Limited | Neurologically-active compounds |
| WO2005095360A1 (en) | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Neurologically-active compounds |
| US8034822B2 (en) * | 2006-03-08 | 2011-10-11 | Takeda San Diego, Inc. | Glucokinase activators |
| BRPI0722382A2 (pt) | 2006-04-14 | 2012-06-05 | Prana Biotechnology Ltd | compostos úteis para o tratamento de cáncer |
| JP4876690B2 (ja) * | 2006-04-21 | 2012-02-15 | 三菱瓦斯化学株式会社 | キナゾリン−４−オン誘導体の製造法 |
| JP5450407B2 (ja) * | 2007-07-06 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 置換アミノ−キナゾリノン、前記化合物を含む薬物、それらの使用及び製造方法 |
| ES2523925T3 (es) * | 2007-09-26 | 2014-12-02 | Celgene Corporation | Derivados de quinazolinona sustituidos en posición 6, 7 u 8 y composiciones que los contienen y métodos de uso de los mismos |
| ES2634492T3 (es) * | 2008-12-24 | 2017-09-28 | Prana Biotechnology Ltd | Compuestos de quinazolinona |
| US8592485B2 (en) * | 2010-06-17 | 2013-11-26 | Healthpartners Research Foundation | Methods and pharmaceutical compositions for treating the animal central nervous system for psychiatric disorders |
| WO2012066330A1 (en) | 2010-11-17 | 2012-05-24 | Heptares Therapeutics Limited | Compounds useful as a2a receptor inhibitors |
| EP2565186A1 (en) * | 2011-09-02 | 2013-03-06 | Hybrigenics S.A. | Selective and reversible inhibitors of ubiquitin specific protease 7 |
| US10260089B2 (en) | 2012-10-29 | 2019-04-16 | The Research Foundation Of The State University Of New York | Compositions and methods for recognition of RNA using triple helical peptide nucleic acids |
| US8877766B2 (en) * | 2013-02-15 | 2014-11-04 | Peter F. Kador | Neuroprotective multifunctional antioxidants and their monofunctional analogs |
| TWI698436B (zh) | 2014-12-30 | 2020-07-11 | 美商佛瑪治療公司 | 作為泛素特異性蛋白酶７抑制劑之吡咯并及吡唑并嘧啶 |
| MA41291A (fr) | 2014-12-30 | 2017-11-07 | Forma Therapeutics Inc | Dérivés de la pyrrolotriazinone et de l'imidazotriazinone en tant qu'inhibiteurs de la protéase spécifique de l'ubiquitine n° 7 (usp7) pour le traitement d'un cancer |
| HK1248221A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 异噻唑啉酮类，吡唑并嘧啶酮类和吡咯并嘧啶酮作为泛蛋白特异性蛋白酶7抑制剂 |
| HK1248220A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 喹唑啉酮和偶氮喹唑啉作为泛特丁胺蛋白酶7抑制剂 |
| HK1248222A1 (zh) | 2015-02-05 | 2018-10-12 | Forma Therapeutics, Inc. | 噻吩并嘧啶酮作为泛素特异性蛋白酶7抑制剂 |
| US10781178B2 (en) | 2015-08-12 | 2020-09-22 | The General Hospital Corporation | 8-hydroxyquinoline derivatives as diagnostic and therapeutic agents |
| AU2018341781B2 (en) | 2017-09-28 | 2023-03-30 | Cstone Pharmaceuticals | Fused ring derivative as A2A receptor inhibitor |
| CN110330487B (zh) * | 2019-07-31 | 2023-03-24 | 西南大学 | 喹唑酮噻唑化合物及其制备方法和应用 |
| TW202208355A (zh) | 2020-05-04 | 2022-03-01 | 美商安進公司 | 作為骨髓細胞觸發受體2促效劑之雜環化合物及使用方法 |
| JP7741100B2 (ja) * | 2020-05-04 | 2025-09-17 | アムジェン インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| KR20240026911A (ko) * | 2021-05-04 | 2024-02-29 | 비질 뉴로사이언스 인코포레이티드 | 골수성 세포 2 작용제 상에서 발현되는 유발 수용체로서의 헤테로고리 화합물 및 사용 방법 |
| EP4430022A4 (en) * | 2021-11-09 | 2025-09-10 | Vigil Neuroscience Inc | HETEROCYCLIC COMPOUNDS USED AS AGONISTS OF THE TRIGGER RECEPTOR EXPRESSED ON MYELOID CELLS 2 AND METHODS OF USE |
| JP2024544553A (ja) * | 2021-11-09 | 2024-12-03 | ビジル・ニューロサイエンス・インコーポレイテッド | ミエロイド細胞に発現するトリガー受容体２アゴニストとしての複素環化合物及び使用方法 |
| WO2025059726A1 (en) * | 2023-09-22 | 2025-03-27 | Alterity Therapeutics Limited | Novel therapy |
| WO2026011223A1 (en) * | 2024-07-12 | 2026-01-15 | Alterity Therapeutics Limited | Novel salt and crystalline form |
| WO2026020054A1 (en) * | 2024-07-18 | 2026-01-22 | Neumora Therapeutics, Inc. | Compounds and methods for treating neurological disorders |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE505711A (enExample) | 1950-09-09 | |||
| US5756502A (en) * | 1994-08-08 | 1998-05-26 | Warner-Lambert Company | Quinazolinone derivatives as cholyecystokinin (CCK) ligands |
| WO1997010221A1 (en) | 1995-09-15 | 1997-03-20 | Torrey Pines Institute For Molecular Studies | Synthesis of quinazolinone libraries |
| WO1998021186A1 (en) | 1996-11-13 | 1998-05-22 | Cephalon, Inc. | Benzothiazo and related heterocyclic group-containing cysteine and serine protease inhibitors |
| AU5380398A (en) | 1996-12-17 | 1998-07-15 | E.I. Du Pont De Nemours And Company | Fungicidal quinazolinones |
| US6337332B1 (en) * | 1998-09-17 | 2002-01-08 | Pfizer Inc. | Neuropeptide Y receptor antagonists |
| SK5222001A3 (en) * | 1998-10-22 | 2002-05-09 | Neurosearch As | Substituted phenyl derivatives, their preparation and use |
| JP4831906B2 (ja) | 1999-08-27 | 2011-12-07 | ケモセントリックス， インコーポレイテッド | Ｃｘｃｒ３機能を調節するための複素環式化合物および方法 |
| ES2263501T3 (es) | 1999-10-27 | 2006-12-16 | Cytokinetics, Inc. | Procedimiento y composiciones que utilizan quinazolinonas. |
| US6545004B1 (en) | 1999-10-27 | 2003-04-08 | Cytokinetics, Inc. | Methods and compositions utilizing quinazolinones |
| DK2223922T3 (en) | 2000-04-25 | 2016-06-06 | Icos Corp | Inhibitors of HUMANPHOSPHATIDYL-inositol 3-KINASEDELTA |
| US6667300B2 (en) * | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
| JP2004515543A (ja) | 2000-12-11 | 2004-05-27 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 有害無脊椎動物を防除するためのキナゾリノン類およびピリジニルピリミジノン類 |
| AU2002363429B2 (en) | 2001-11-07 | 2008-05-08 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7053216B2 (en) | 2001-11-19 | 2006-05-30 | Iconix Pharmaceuticals, Inc. | Modulators of Rho C activity |
| WO2003043995A1 (en) | 2001-11-20 | 2003-05-30 | Cytokinetics, Inc. | Process for the racemization of chiral quinazolinones |
| AU2003213092A1 (en) | 2002-02-15 | 2003-09-09 | Smithkline Beecham Corporation | Syntheses of quinazolinones |
| EP1521746B1 (en) | 2002-03-07 | 2011-04-27 | X-Ceptor Therapeutics, Inc. | Quinazolinone modulators of nuclear receptors |
| US6900219B2 (en) | 2002-04-04 | 2005-05-31 | Cv Therapeutics, Inc. | ABCA-1 elevating compounds |
| AU2002950217A0 (en) * | 2002-07-16 | 2002-09-12 | Prana Biotechnology Limited | 8- Hydroxy Quinoline Derivatives |
| AU2003262747A1 (en) * | 2002-08-21 | 2004-03-11 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| EP1558585B1 (en) | 2002-10-04 | 2013-09-25 | Prana Biotechnology Limited | Neurologically-active compounds |
| US9301829B2 (en) | 2003-07-30 | 2016-04-05 | Boston Scientific Scimed, Inc. | Embolic protection aspirator |
| US20050054614A1 (en) | 2003-08-14 | 2005-03-10 | Diacovo Thomas G. | Methods of inhibiting leukocyte accumulation |
| US20050043239A1 (en) * | 2003-08-14 | 2005-02-24 | Jason Douangpanya | Methods of inhibiting immune responses stimulated by an endogenous factor |
| WO2005051922A1 (en) | 2003-11-25 | 2005-06-09 | Chiron Corporation | Quinazolinone compounds as anticancer agents |
| CA2552664A1 (en) | 2004-01-08 | 2005-07-28 | Michigan State University | Methods for treating and preventing hypertension and hypertension-related disorders |
| WO2005095360A1 (en) | 2004-04-02 | 2005-10-13 | Prana Biotechnology Limited | Neurologically-active compounds |
| WO2005112935A1 (en) | 2004-05-13 | 2005-12-01 | Vanderbilt University | Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis |
| AU2005247808B2 (en) | 2004-05-31 | 2011-02-10 | Msd K.K. | Quinazoline derivative |
| WO2005120511A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
| US20050282834A1 (en) * | 2004-06-09 | 2005-12-22 | Fady Malik | Compositions, devices and methods for treating cardiovascular disease |
-
2005
- 2005-04-01 WO PCT/AU2005/000477 patent/WO2005095360A1/en not_active Ceased
- 2005-04-01 CA CA2563038A patent/CA2563038C/en not_active Expired - Lifetime
- 2005-04-01 EP EP05714346.3A patent/EP1737831B1/en not_active Expired - Lifetime
- 2005-04-01 DK DK05714346.3T patent/DK1737831T3/da active
- 2005-04-01 MX MXPA06011236A patent/MXPA06011236A/es active IP Right Grant
- 2005-04-01 US US11/547,056 patent/US8084459B2/en not_active Expired - Lifetime
- 2005-04-01 ES ES05714346T patent/ES2425476T3/es not_active Expired - Lifetime
- 2005-04-01 JP JP2007505341A patent/JP4937111B2/ja not_active Expired - Fee Related
- 2005-04-01 BR BRPI0508183A patent/BRPI0508183B8/pt not_active IP Right Cessation
- 2005-04-01 NZ NZ551004A patent/NZ551004A/en not_active IP Right Cessation
-
2006
- 2006-09-27 IL IL178330A patent/IL178330A/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2078578C (en) | Medical use for tachykinin antagonists | |
| DE60017898T2 (de) | Neuartige heterocyclische carboxamidderivate | |
| EP2813498B1 (en) | Compounds for Alzheimer's disease | |
| CA2500952A1 (en) | Neurologically-active compounds | |
| JPH07324076A (ja) | 新規なピラゾール−３−カルボキサミド誘導体、これらを製造するための方法及びこれらが存在する薬学的組成物 | |
| DE69529418T2 (de) | Cyclopropachromencarbonsäure derivate | |
| WO2002012189A1 (en) | Fused bicyclic amide compounds and medicinal use thereof | |
| JP6261011B2 (ja) | 眼疾患処置薬 | |
| BG65193B1 (bg) | Производно на пиразолкарбоксилна киселина, неговото използване и фармацевтични състави, които го съдържат | |
| RU2005100842A (ru) | Производные 8-гидроксихинолина | |
| JP2011507878A5 (enExample) | ||
| CN103781753B (zh) | 用于治疗ape1介导的疾病的醌化合物 | |
| JP4937111B2 (ja) | 神経学的に活性な化合物 | |
| JP2005531488A5 (enExample) | ||
| MXPA04002338A (es) | Derivados de carbazol y su uso como antagonistas receptores del npy5. | |
| JP2011507879A5 (enExample) | ||
| JP2007523909A5 (enExample) | ||
| JP2004507527A5 (enExample) | ||
| JPH02503909A (ja) | ６．１１‐ジヒドロ‐１１‐（４‐ピペリジリデン）‐５Ｈ‐ベンゾ［５，６］シクロヘプタ［１，２‐ｂ］ピリジン類ならびに組成物および使用法 | |
| JP6219955B2 (ja) | ベンゾフラザン抗アミロイド化合物および方法 | |
| KR20060132953A (ko) | 지양제 | |
| RU2003101396A (ru) | Замещенные нитрированные катехолы, их применение в лечении некоторых расстройств центральной и периферической нервной системы и содержащие их фармацевтические композиции | |
| JPS6056957A (ja) | エチレンジアミン誘導体 | |
| JP5341521B2 (ja) | タンパク質と結合パートナーとの相互作用を阻害するための化合物及び方法 | |
| CA2589744A1 (en) | Pyrrolinidium derivatives as m3 muscarinic receptors |